natgillin/translations-raw huggingface dataset:
You need to keep taking it every day to control your infection and stop your illness getting worse.
Zdravilo Zeffix pomaga nadzorovati vašo okužbo s hepatitisom B. Jemati ga morate vsak dan, da bo vaša okužba kontrolirana in da se vaša bolezen ne bo slabšala.
Do not store above 25 ºC.
Shranjujte pri temperaturi do 25 ºC.
Limited data in patients undergoing liver transplantation show that impairment of hepatic function does not impact significantly on the pharmacokinetics of lamivudine unless accompanied by renal dysfunction.
Omejeni podatki pri bolnikih s transplantacijo jeter kažejo, da farmakokinetika lamivudina pri oslabljeni jetrni funkciji ni znatno prizadeta, vendar slednje ne velja pri sočasni ledvični disfunkciji.
However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food.
Sočasno jemanje lamivudina s hrano ima za posledico zakasnitev tmax in zmanjšanje Cmax (zmanjšanje za do 47 %), vendar na obseg (na osnovi AUC) absorpcije lamivudina ne vpliva, torej se lamivudin lahko daje s hrano ali brez nje.
ALT  2 x baseline value and absolute ALT > 500 IU/l
ALT ≥ 2 x osnovna vrednost in absolutni ALT
Don't store above 25 °C.
Shranjujte pri temperaturi do 25 °C.
 Use a condom when you have oral or penetrative sex.  Don't risk blood transfer - for example, don't share needles.
 Ne tvegajte okužbe s krvjo - na primer ne uporabljajte injekcijskih igel skupaj z drugimi.
For patients who develop evidence of recurrent hepatitis post-treatment, there are insufficient data on the benefits of re-initiation of lamivudine treatment.
O koristih ponovne uvedbe zdravljenja z lamivudinom pri bolnikih, ki se jim po zdravljenju pojavijo znaki ponovnega hepatitisa, ni dovolj podatkov.
Zeffix 100 mg film-coated tablets lamivudine
Zeffix 100 mg filmsko obložene tablete lamivudin
Experience in CHB patients with advanced fibrosis or cirrhosis In a placebo-controlled study in 651 patients with clinically compensated chronic hepatitis B and histologically confirmed fibrosis or cirrhosis, lamivudine treatment (median duration 32 months) significantly reduced the rate of overall disease progression (34/436, 7.8 % for lamivudine versus 38/215, 17.7 % for placebo, p=0.001), demonstrated by a significant reduction in the proportion of patients having increased Child-Pugh scores (15/436, 3.4 % versus 19/215, 8.8 %, p=0.023) or developing hepatocellular carcinoma (17/436, 3.9 % versus 16/215, 7.4 %, p=0.047).
mesecev) pomembno zmanjšalo odstotek celokupnega napredovanja bolezni (pri 34/436 oz. 7,8 % bolnikov, ki so se zdravili z lamivudinom, v primerjavi z 38/215 oz. 17,7 % bolnikov, ki so prejemali placebo, p=0,001), kar se je kazalo kot značilno zmanjšanje odstotka bolnikov, pri katerih se je povečal Child-Pugh-jev indeks (15/436 oz. 3,4 % v primerjavi z 19/215 oz. 8,8 %, p=0,023) ali pri katerih se je razvil hepatocelularni karcinom (17/436 oz. 3,9 % v primerjavi z 16/215 oz. 7,4 %, p=0,047).
Patients categorised as non-YMDD mutant were those with > 95% wild-type HBV at all annual time-points during the 5-year study period
Bolniki z YMDD mutantom so bolniki, ki so v obdobju 5-ih let imeli v kateremkoli časovnem obdobju ≥ 5 % YMDD mutana HBV. Bolniki brez YMDD mutanta so bolniki, ki so med 5 letnim trajanjem študije v vseh časovnih obdobjih imeli ≥ 95 % divjega tipa HBV.
There were no observed clinically significant adverse interactions in patients taking lamivudine concurrently with commonly used immunosuppressant medicinal products (e.g. cyclosporin A).
Pri bolnikih, ki so sočasno jemali lamivudin in pogosto uporabljana imunosupresivna zdravila (npr. ciklosporin A), ni bilo opaznih klinično pomembnih neželenih interakcij.
Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline.
Spontana poslabšanja kroničnega hepatitisa B so razmeroma pogosta; značilna zanje so prehodna zvišanja serumske ALT.
Experience in patients with HBeAg positive CHB and compensated liver disease In controlled studies, 1 year of lamivudine therapy significantly suppressed HBV DNA replication (34-57 % of patients were below the assay detection limits (Abbott Genostics solution hybridization assay, LLOD < 1.6pg/ml)], normalised ALT level (40-72 % of patients), induced HBeAg seroconversion (HBeAg loss and HBeAb detection with HBV DNA loss [by conventional assay], 1618 % of patients), improved histology (38-52 % of patients had a  2 point decrease in the Knodell Histologic Activity Index [HAI]) and reduced progression of fibrosis (in 3-17 % of patients) and progression to cirrhosis.
Izkušnje pri HBeAg pozitivnih bolnikih s CHB in kompenzirano jetrno boleznijo V nadzorovanih študijah je enoletno zdravljenje z lamivudinom znatno zavrlo replikacijo HBV DNA [pri 34 do 57 % bolnikov je bila pod mejo dokazljivosti s testom (Abbott Genostics hibridizacijski test v raztopini, LLOD < 1,6 pg/ml)], normaliziralo aktivnost ALT (pri 40 do 72 % bolnikov), sprožilo serokonverzijo HBeAg (izginotje HBeAg ter pojav protiteles HBeAb z izginotjem HBV DNA [z običajnimi testi] pri 16 do 18 % bolnikov), izboljšalo histološko sliko (pri 38 do 52 % bolnikov se je
- Baseline 3
- Izhodiščna vrednost3
• if you're allergic to lamivudine or to any of the other ingredients of this medicine (listed in Section 6).
• če ste alergični na lamivudin ali katerokoli drugo sestavino tega zdravila (navedeno v poglavju Posvetujte se z zdravnikom, če mislite, da to velja za vas.
A common side effect (these may affect up to 1 in 10 people) is:
Pogost neželeni učinek (pojavi se lahko pri največ 1 od 10 bolnikov) je:
The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal elimination of unchanged substance.
Zaradi omejene presnove in vezave na plazemske proteine ter skoraj popolnega izločanja nespremenjene učinkovine skozi ledvice je verjetnost presnovnih interakcij nizka.
Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance.
Zaradi zmanjšanega očistka pri bolnikih z zmernim do hudo oslabljenim delovanjem ledvic so serumske koncentracije (AUC) lamivudina zvečane.
For HIV co-infected patients not requiring anti-retroviral therapy, there is a risk of HIV mutation when using lamivudine alone for treating chronic hepatitis B.
Med zdravljenjem kroničnega hepatitisa B samo z lamivudinom pri bolnikih, ki so sočasno okuženi z virusom HIV in odklanjajo protiretrovirusno zdravljenje, obstaja tveganje za mutacijo virusa HIV.
In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting.
Posledica tega je možno tveganje za neučinkovitost kladribina v primeru kombinirane klinične uporabe.
Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see section decompensated liver disease in combination with a second agent, without cross-resistance to lamivudine (see section 4.2).
Začetek zdravljenja z lamivudinom pride v upoštev le, kadar uporaba drugega protivirusnega zdravila z višjo genetsko pregrado proti odpornosti ni na razpolago oz. ni primerna (glejte poglavje 5.1).
Don't store above 30 °C.
Shranjujte pri temperaturi do 30 °C.
First dose of Zeffix oral solution *
Zeffix peroralne raztopine *
Sucrose (20 % w/v) Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Citric acid (anhydrous) Propylene glycol
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi saharoza (20 % w/v) metilparahidroksibenzoat (E218) propilparahidroksibenzoat (E216) citronska kislina (brezvodna) propilenglikol natrijev citrat umetna aroma jagode umetna aroma banane prečiščena voda
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Zeffix.
Če dojite, ali razmišljate o dojenju: se posvetujte z zdravnikom, preden vzamete zdravilo Zeffix.
- Baseline normal above normal
- Izhodiščna vrednost normalna vrednost vrednost višja od normalne vrednosti
In patients without the mutant, 20/27 (74 %) had improvements in necroinflammatory activity and 2/27 (7 %) had worsening.
Pri bolnikih brez YMDD mutanta je prišlo do izboljšanja nekrotičnih in vnetnih sprememb pri 20/27 (74 %) bolnikov, do poslabšanja pa pri 2/27 (7 %) bolnikov.
Excipient intolerance
Intoleranca na pomožne snovi
Consider more frequent monitoring of HBV viral load when chronic co-administration cannot be avoided.
Če pa se kronični sočasni uporabi ni mogoče izogniti, pogosteje kontrolirajte virusno breme HIV-1.
Zeffix 5 mg/ml oral solution lamivudine
Zeffix 5 mg/ml peroralna raztopina lamivudin
In a long-term follow-up study of patients who had previously seroconverted and discontinued lamivudine, late virological relapse occurred in 39 % of the subjects.
39 % oseb prišlo do poznega virusnega relapsa.
There is no information available on maternal-foetal transmission of hepatitis B virus in pregnant women receiving treatment with lamivudine.
Pri nosečnicah, ki se zdravijo z lamivudinom, je malo podatkov o prenosu virusa hepatitisa B z matere na plod.
Based on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.
Na osnovi teh podatkov pri bolnikih z jetrno okvaro, razen v primeru sočasnega oslabljenega delovanja ledvic, odmerka ni treba prilagajati.
If you get any side effects, talk to your doctor or pharmacist.
- Če opazite katerikoli neželeni učinek, se posvetujte s svojim zdravnikom ali farmacevtom.
• cladribine, used to treat hairy cell leukaemia Tell your doctor if you're being treated with any of these.
• kladribin, ki se uporablja pri zdravljenju dlakastocelične levkemije.
You must not stop taking Zeffix without consulting your doctor.
Ne prenehajte z jemanjem zdravila Zeffix, če se o tem predhodno niste posvetovali z zdravnikom.
How to store Zeffix
Shranjevanje zdravila Zeffix
Exacerbations of hepatitis
Poslabšanja hepatitisa Poslabšanja med zdravljenjem
PHARMACEUTICAL FORM AND CONTENTS Each bottle contains 240 ml oral solution
Ena plastenka vsebuje 240 ml peroralne raztopine
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR ORAL SOLUTION
PODATKI NA ZUNANJI OVOJNINI ZUNANJA OVOJNINA ZA PERORALNO RAZTOPINO
of patients with pre-treatment ALT > 2 x ULN seroconverted.
- Bolniki z izhodiščno vrednostjo ALT ≤ 1 x ZMN2 - Bolniki z izhodiščno vrednostjo ALT > 2 x ZMN
NAME OF THE MEDICINAL PRODUCT Zeffix 5 mg/ml oral solution Lamivudine
Navodilo za uporabo Zeffix 5 mg/ml peroralna raztopina lamivudin
Each ml of oral solution contains 5 mg of lamivudine.
Vsak ml peroralne raztopine vsebuje 5 mg lamivudina.
Each ml of the oral solution contains 5 mg lamivudine
En ml peroralne raztopine vsebuje 5 mg lamivudina
NAME OF THE MEDICINAL PRODUCT Zeffix 100 mg film-coated tablets Lamivudine
Navodilo za uporabo Zeffix 100 mg filmsko obložene tablete lamivudin
The oral solution contains propyl and methyl parahydroxybenzoate.
Peroralna raztopina vsebuje propilparahidroksibenzoat in metilparahidroksibenzoat, ki lahko pri posameznikih povzročita alergijsko reakcijo.
If you get any side effects Talk to your doctor or pharmacist.
Če se vam pojavi kakšen neželeni učinek se posvetujte s svojim zdravnikom ali farmacevtom.
In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels.
(tirozin-metionin-aspartat-aspartat) mutanta HBV zmanjša terapevtski odziv na lamivudin; to se kaže s porastom HBV-DNA in ALT v primerjavi s predhodnimi ravnmi med zdravljenjem.
Always take this medicine exactly as your doctor has told you to.
Pri jemanju tega zdravila natančno upoštevajte zdravnikova navodila.
• difficulty swallowing or breathing Contact a doctor immediately if you get these symptoms.
Nemudoma se posvetujte z zdravnikom, če se vam pojavijo ti simptomi.
EFFECTIVE USE OF THE MEDICINAL PRODUCT
PROMET Z ZDRAVILOM
Talk to your doctor or pharmacist.
Če ste negotovi, se posvetujte z zdravnikom ali farmacevtom.
NAME OF THE MEDICINAL PRODUCT Zeffix 100 mg film-coated tablets
Zeffix 100 mg filmsko obložene tablete
The likelihood of metabolic substance interactions with lamivudine is low due to the small (5-10 %) extent of hepatic metabolism and the low plasma protein binding.
obsega jetrne presnove in majhne vezave na plazemske proteine je verjetnost interakcij presnovnih substanc z lamivudinom majhna.
Polysorbate 80
NUCB3018
Tabulated list of adverse reactions
Prikaz neželenih učinkov v preglednici
Zeffix contains sucrose.
Zeffix peroralne raztopine
PHARMACEUTICAL FORM Oral solution
SEZNAM POMOŽNIH SNOVI FARMACEVTSKA OBLIKA IN VSEBINA
The pharmacokinetics of lamivudine are unaffected by hepatic impairment.
Pri oslabljenem delovanju jeter ostane farmakokinetika lamivudina nespremenjena.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 28 tablet box, 84 tablet box
škatla z 28 tabletami, škatla s 84 tabletami
This summary was last updated in December 2012.
Povzetek je bil nazadnje posodobljen decembra 2012.
The European Commission granted a marketing authorisation valid throughout the European Union, for Prac-tic to on 18 December 2006.
Evropska komisija je dovoljenje za promet z zdravilom Prac-tic, veljavno po vsej Evropski uniji, odobrila dne 18. decembra 2006.
Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children.
Nedavno zdravljene živali ne smejo spati v isti postelji s svojimi lastniki, zlasti ne z otroki.
Other information about Prac-tic:
Druge informacije o zdravilu Prac-tic:
Two field studies were conducted in dogs at veterinary practices in several European countries and different geographic regions.
Dve terenski preskušanji sta bili izvedeni pri psih v veterinarskih ambulantah v nekaterih evropskih državah in v različnih geografskih regijah.
Prac-tic should not be used in dogs less than 8 weeks old or less than 2 kg bodyweight since it has not sufficiently been studied in these animals.
Zdravilo Prac-tic se ne sme uporabljati pri psih, ki so stari manj kot 8 tednov ali imajo manj kot 2 kg telesne mase, saj pri teh skupinah živali zdravilo ni bilo zadostno raziskano.
This product is specifically developed for dogs and should not be used in any other animal species.
To zdravilo je bilo razvito posebej za pse in se ne sme uporabljati pri drugih živalskih vrstah.
For large dogs a combination of pipettes might be needed to achieve the correct dose.
Pri večjih psih bo morda treba uporabiti kombinacijo več merilnih kapalk, da se doseže ustrezni odmerek.
Data were provided on the pharmaceutical quality, the tolerance of the product in dogs and the safety in humans (people in contact with the product) and the environment.
Predloženi so bili podatki o farmacevtski kakovosti, toleranci na zdravilo pri psih ter njegovi varnosti za ljudi (ljudi, ki pridejo v stik z zdravilom) in okolje.
The medicine killed fleas within 24 hours and ticks within 48 hours after treatment and its effectiveness lasted for at least 4 weeks.
Zdravilo uniči bolhe v 24 urah, klope pa v 48 urah po uporabi zdravila, njegov učinek pa traja najmanj 4 tedne.
Pyriprole, interacts with a receptor involved in transmitting neural impulses (GABA receptor).
Piriprol vzajemno deluje z receptorjem, ki igra vlogo pri prenosu živčnih dražljajev (receptorjem GABA).
This interferes with the nervous system of fleas or ticks and leads to the death of these parasites.
To zaviralno deluje na živčni sistem bolh ali klopov ter povzroči smrt teh zajedavcev.
What benefit has Prac-tic shown during the studies?
Kakšne koristi je zdravilo Prac-tic izkazalo med študijami?
The effectiveness was measured looking at the number of live ticks or number of fleas at various times up to 3 months after application.
Učinkovitost so merili z ugotavljanjem števila živih klopov ali števila bolh ob različnih časovnih obdobjih, in sicer do 3 mesecev po uporabi zdravila.
Pyripole
Prac-tic piriprol
As a precautionary measure, direct contact with the treated dog should be avoided and children should not be allowed to play with a treated animal until the application site is dry.
Iz preventivnih razlogov se je treba izogibati neposrednemu stiku z zdravljenim psom in preprečiti otrokom igranje z zdravljeno živaljo, dokler področje nanosa ni suho.
What is the risk associated with Prac-tic?
Kakšna tveganja so povezana z zdravilom Prac-tic?
As other products of this group, Prac-tic should not be used in sick animals or dogs that have just recovered from illness.
Kot to velja za ostala zdravila iz te skupine zdravil, se zdravilo Prac-tic ne sme uporabljati pri bolnih živalih ali psih, ki so pravkar okrevali po bolezni.
Prac-tic should not be allowed to enter surface water, as it may be harmful for aquatic organisms.
Zdravilo Prac-tic ne sme zaiti v vodotoke, ker je lahko nevarno za vodne organizme.
Skin contact with the pipette content should be avoided.
Stiku vsebine merilne kapalke s kožo se je treba izogibati.
The effectiveness of pyriprole against flea and tick infestations in dogs was investigated in laboratory studies and in field trials.
Učinkovitost piriprola zoper infestacije z bolhami in klopi pri psih je bila raziskana v laboratorijskih raziskavah in terenskih preskušanjih.
Dogs from various breeds, age groups and weight that were infested with fleas or ticks were either treated with Prac-tic or with other products authorised in the EU for this indication.
Pse različnih ras, starostnih skupin in z različnimi telesnimi masami, ki so bili infestirani z bolhami in klopi, so zdravili bodisi z zdravilom Prac-tic bodisi z drugimi zdravili, ki so bila v EU odobrena za to indikacijo.
It is given to dogs with pre-filled spot-on pipettes, i.e. small plastic containers which are already filled with the correct amount of Prac-tic needed to treat one dog (Pract-tic is available in 4 different sizes for different dog sizes).
majhnimi plastičnimi cevkami, ki so že napolnjene z ustrezno količino zdravila Prac-tic, potrebno za zdravljenje enega psa (zdravilo Prac-tic je na voljo v 4 različnih velikostih, ki ustrezajo različnim velikostim psov).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Prac-tic exceed the risks for the approved indications and recommended that Prac-tic be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Prac-tic večje od z njim povezanih tveganj, kadar se zdravilo uporablja za odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
The most common side effects in dogs are local reactions at the place where the product has been applied: change in the fur colour, hair loss and itchiness, as well as change in appearance of the fur (greasy appearance and clumpiness).
Najpogostejši neželeni učinki pri psih so lokalne reakcije na mestu nanosa zdravila: sprememba barve dlak, izpadanje dlak in srbečica ter sprememba videza dlak (masten videz in sprijete dlake).
If a dog licks the application area, the dog might salivate a lot for a short period.
Če pes liže mesto nanosa, se lahko pri njem pojavi kratko obdobje prekomernega slinjenja.
Why has Prac-tic been approved?
Zakaj je bilo zdravilo Prac-tic odobreno?
The results of the field trials showed that Prac-tic is effective in the treatment and prevention of flea and tick infestations in dogs.
Rezultati terenskih preskušanj so pokazali, da je zdravilo Prac-tic učinkovito pri zdravljenju in preprečevanju infestacij z bolhami in klopi pri psih.
Prac-tic is an “ectoparasiticide”, which means that it will kill parasites that live on the skin or in the fur of animals, such as fleas and ticks.
Prac-tic je zdravilo za zatiranje zunanjih zajedavcev, kar pomeni, da uničuje zajedavce, ki živijo na koži ali v dlaki živali, kot so denimo bolhe in klopi.
Prac-tic is used to treat and to prevent tick and flea infestations in dogs.
Zdravilo Prac-tic se uporablja za zdravljenje in preprečevanje infestacij s klopi in bolhami pri psih.
The content of the pipette is squeezed onto the skin after parting the fur in one up to three spots between the shoulder blades and down the backline of the dog.
Psu razmaknemo dlako na enem do treh mestih med lopaticama in vzdolž njegove hrbtenice tako, da se prikaže koža, in na ta mesta stisnemo vsebino merilne kapalke.
What is Prac-tic used for?
Za kaj se zdravilo Prac-tic uporablja?
How has Prac-tic been studied?
Kako je bilo zdravilo Prac-tic raziskano?
Once applied, it remains active for at least 4 weeks.
Učinek zdravila traja najmanj 4 tedne po njegovi uporabi.
People with known hypersensitivity to the phenylpyrazole class compounds or any of the excipients should avoid contact with Prac-tic.
Stiku z zdravilom Prac-tic se morajo izogibati tudi ljudje, ki so preobčutljivi na snovi iz skupine fenilpirazolov ali na katere koli druge pomožne snovi zdravila.
Adult fleas are killed before they lay eggs; since Prac-tic completely eliminates egg production, it breaks the flea life cycle.
S tem ko zdravilo Prac-tic povsem ustavi proizvodnjo jajčec, se življenjski cikel bolh prekine.
Skin should be washed and eyes should be rinsed with water, if accidental exposure occurred.
V primeru nenamernega stika je treba kožo in oči sprati z vodo.
How does Prac-tic work?
Kako zdravilo Prac-tic deluje?
Prac-tic is a spot-on solution that contains pyriprole as active substance.
Zdravilo Prac-tic je na voljo v obliki raztopine za kožne kapljice, ki vsebuje zdravilno učinkovino piriprol.
What is Prac-tic?
Kaj je zdravilo Prac-tic?
When administering Prac-tic, the user should not smoke, eat or drink.
Ne kadite, jejte ali pijte, medtem ko rokujete z zdravilom Prac-tic.
50 x 1 tablet(unit dose) 105 tablets
50 x 1 tableta (enoodmerni pretisni omot)
EMA Number
Številka postopka EMA Ime
Desloratadine Teva Desloratadine Teva
Pot uporabe Ovojnina
This finding was based on the results from 769 patients.
Te ugotovitve so temeljile na izidih študije pri 769 bolnikih.
To manage side effects, treatment may have to be temporarily interrupted or the dose may be reduced.
Za obvladovanje neželenih učinkov bo morda treba zdravljenje začasno prekiniti ali zmanjšati odmerek.
The European Commission granted a marketing authorisation valid throughout the European Union for Nexavar on 19 July 2006.
Evropska komisija je dovoljenje za promet z zdravilom Nexavar, veljavno po vsej Evropski uniji, izdala 19. julija 2006.
EPAR summary for the public sorafenib
Povzetek EPAR za javnost sorafenib
Nexavar is given as two tablets twice a day, without food or with a meal that is low in fat.
Zdravilo Nexavar se daje v dveh tabletah dvakrat na dan bodisi brez hrane ali z obrokom, ki vsebuje malo maščobe.
Because the numbers of patients with these diseases are low, the diseases are considered ‘rare', and Nexavar was designated an ‘orphan medicine' (a medicine used in rare diseases).
Ker je bolnikov s temi boleznimi malo, veljajo bolezni za redke, zato je bilo zdravilo Nexavar določeno kot „zdravilo sirota“ (zdravilo, ki se uporablja pri redkih boleznih).
Other information about Nexavar
Druge informacije o zdravilu Nexavar
This is a summary of the European public assessment report (EPAR) for Nexavar.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Nexavar.
For more information about treatment with Nexavar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Nexavar preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.